Metformin is the indispensable first-line treatment for type 2 diabetes mellitus (DM) worldwide. It prevents the absorption of vitamin B12 in the ileum. It is believed that this mechanism is caused by inhibition of calcium dependent channels in the ileum. It is known that prolonged use of metformin causes vitamin B12 deficiency by this mechanism \[[@ref1]--[@ref5]\]. Vitamin B12 deficiency may lead to neuropsychiatric and hematological abnormalities. The relationship between vitamin B12 deficiency and peripheral neuropathy has been shown in previous studies \[[@ref6]--[@ref7]\].

Herein, we investigated the relationship between vitamin B12 deficiency due to the use of metformin and peripheral neuropathy.

MATERIALS AND METHODS {#sec1-2}
=====================

Eighty-six patients with type 2 DM aged \>18 years who were using metformin were included in the study. The patients' files were retrospectively reviewed. Vitamin B12 levels, age, sex, duration of diabetes, HbA1c levels, and body mass index data were recorded from the archives of the Adıyaman Medical Faculty Hospital. The presence of peripheral neuropathy was determined by electromyography (EMG). Patients with no EMG report and other information were excluded from the study.

All analyses were performed using the SPSS for Windows (version 21.0; SPSS/IBM, Chicago, IL). Descriptive statistics and Mann--Whitney U tests were used when appropriate. The statistical significance level was accepted as a P value of \<0.05.

Results {#sec1-3}
=======

Twenty-six of the patients were males and 60 were females. The mean age of the patients was 55.1±7.7 years. The mean body mass index of the patients was 29.1±9.01 kg/m^2^. The mean HbA1c level of the patients was 8.6%±2.1%. The mean duration of diabetes was 8.02±5.4 years.

The incidence of vitamin B12 deficiency in the patients was 38.4%. Peripheral neuropathy was detected in 29 of the patients (33.7%). The general characteristics of the patients and the laboratory values are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Demographic and clinical features of patients

  Parameters                             n (%) or Mean±SD
  -------------------------------------- ----------------------
  Age                                    55.1±7.7
  Gender (M/F) (%)                       26 (30.2) / 60(69.8)
  HbA1c (%)                              8.6±2.1
  DM duration (years)                    8.02±5.4
  Body Mass Index (kg/m^2^)              29.1±9.01
  Vitamin B12 deficiency frequency (%)   33 (38.4)
  Neuropathy frequency (%)               29 (33.7)

There was no statistically significant differences vitamin B12 levels between patients with peripheral neuropathy and those without peripheral neuropathy (p=0.64). The relationship between peripheral neuropathy and vitamin B12 is shown in [Table 2](#T2){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}.

###### 

Comparison of vitamin B12 levels between the groups

  Parameters    Neuropathy-positive group Mean of Rank   Neuropathy-negative group Mean of Rank   P
  ------------- ---------------------------------------- ---------------------------------------- ------
  Vitamin B12   45.22                                    42.62                                    0.64

![Graphic of vitamin B12 levels between the groups.](NCI-4-233-g001){#F1}

Discussion {#sec1-4}
==========

Metformin is the first and most important treatment for type 2 DM worldwide if there is no contraindication. Metformin leads the insulin sensitizing effect on the liver. Although gastrointestinal side effects are most common because of the use of metformin, it can also lead to serious side effects, such as lactic acidosis and vitamin B12 deficiency \[[@ref8]-[@ref9]\].

In a study by Ko et al., the incidence of vitamin B12 deficiency was increased in patients who have been treated with metformin for ≥4 years and those who have been using high-dose metformin \[[@ref3]\].

Vitamin B12 deficiency can lead to clinically significant but treatable conditions. These include a wide range of clinical conditions, such as memory impairment, peripheral neuropathy, dementia, delirium, subacute combined degeneration of the spinal cord, megaloblastic anemia and pancytopenia.

Studies investigating the relationship between peripheral neuropathy and vitamin B12 deficiency have contradictory results. In a study by Ahmed et al., no significant relationship was found between vitamin B12 vitality deficiency and peripheral neuropathy because of the use of metformin \[[@ref10]\]. Contrary to the results of above study, a study by Singh et al. reported that the use of metformin was significantly associated with vitamin B12 deficiency and peripheral neuropathy \[[@ref11]\]. In a study conducted by Jayabalan et al, vitamin B12 supplementation in patients with diabetic peripheral neuropathy was found to have no effect on healing \[[@ref12]\].

In our study, there was no statistically significant difference in vitamin B12 levels between patients with peripheral neuropathy and those without peripheral neuropathy (p=0.64).

In a study conducted by Raizada et al., no significant increase in the prevalence of neuropathy was found in vitamin B12-deficient patients compared with patients with normal vitamin B12 levels. They emphasized that the increased the duration of diabetes was associated with the severity of vitamin B12 deficiency \[[@ref13]\].

In a letter by Chowta and Tiwary that commented on an article, they emphasized that exhaustion of vitamin B12 stores usually occurs after 12--15 years of absolute vitamin B12 deficiency. Thus, the duration of diabetes is the most crucial point in the development of vitamin B12 associated neuropathy. In our study, the mean diabetes duration was 8.02±5.4 years. Therefore, in future studies, we and other researchers should include a population with longer diabetes duration to further illuminate this point \[[@ref14]\].

In conclusion, it can be said that deficiency of vitamin B12 secondary to the use of metformin in the Adıyaman province does not obviously increase the frequency of peripheral neuropathy.

Finally, this present study had some limitations. These were the small number of patients and the retrospective nature of the study. This issue will be better illuminated in the future by prospective studies with a large number of patients.
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